Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.